PLYMOUTH MEETING, Pa., June 19, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. J. Joseph Kim, President & CEO, will participate on a panel, titled “Platform Technologies: The Key to Responding to Emerging Infectious Diseases,” at the 2017 BIO International Conference at the San Diego Convention Center on Wednesday, June 21, 2017, at 1:45pm PT.
New platform technologies based on important scientific advances are being recognized as the best way to develop vaccines and therapeutics for emergency situations. This panel will explore the latest scientific and clinical advances in the development of such platform technologies, and highlight novel partnerships and approaches that are leveraging such technologies to speed up response times to and the ability to potentially conquer novel pathogens.
Inovio’s DNA-based platform, which is the foundation of all Inovio products, is unique in its ability to leverage the body’s naturally existing mechanisms to generate robust, highly targeted immune responses to prevent and treat disease – and to do so in the body with a favorable safety profile. Its SynCon® immunotherapy design technology allows rapid development of new products to stimulate effective immune responses against targeted infectious diseases and cancers. Inovio has demonstrated this rapid and robust capability with its vaccines for HIV, Ebola, MERS and Zika, where the immune response rates consistently ranged from 90 to 100% in phase 1 studies. In fact, Inovio’s Zika vaccine advanced from concept design to the start of human trials in about six months, establishing this product as having one of the fastest times for such development. These results have validated the potential of Inovio’s technology platform to respond rapidly to global health emergencies.
About Inovio Pharmaceuticals, Inc.
Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Regeneron Pharmaceuticals, Genentech, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, The Wistar Institute, Laval University, University of Pennsylvania, Drexel University, DARPA, NIH, HIV Vaccines Trial Network, National Cancer Institute, and U.S. Military HIV Research Program. For more information, visit www.inovio.com.
This press release contains certain forward-looking statements relating to our business. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including the availability and timing of data from ongoing clinical trials, uncertainties inherent in the completion of ongoing clinical trials and the initiation of future clinical trials, whether the results of earlier clinical trials will be indicative of the results of future trials, expectations for regulatory approvals, the availability of funding to support continuing research and studies, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its collaborators hope to develop and other factors discussed in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2016, filed with the U.S. Securities and Exchange Commission (SEC) on March 15, 2017, our Form 10-Q for the quarter ended March 31, 2017, filed with the SEC on May 10, 2017, and other filings that Inovio makes with the SEC from time to time. There can be no assurance that any product candidate in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical trials will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.
In addition, the forward-looking statements included in this press release represent Inovio’s views as of the date hereof. Inovio anticipates that subsequent events and developments may cause its views to change. However, while Inovio may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing Inovio’s views as of any date subsequent to the date of this release.
CONTACT: CONTACTS: Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, email@example.com Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, firstname.lastname@example.org